Overall, more clinicians preferred anti-VEGF as the first-line treatment for posterior disease (A-ROP, Type 1 ROP in zone 1, posterior zone 2); and laser for anterior disease (Type 1 ROP in anterior zone 2 and zone 3). The gene discussed is VEGFA; the disease is retinopathy of prematurity.